Wogonin mitigates intervertebral disc degeneration through the Nrf2/ARE and MAPK signaling pathways

Int Immunopharmacol. 2018 Dec:65:539-549. doi: 10.1016/j.intimp.2018.10.024. Epub 2018 Nov 6.

Abstract

Intervertebral disc degeneration (IVDD) is a prevalent disease characterized by the progressive loss of the extracellular matrix in the local nucleus pulposus region. Metalloproteinases and pro-inflammatory cytokines play an important role in this process. Thus, anti-inflammatory strategies are an important component of IVDD treatment. Wogonin, a naturally existing monoflavonoid, has been reported to have potential anti-inflammatory effects in some inflammatory diseases. Hence, in our present study we investigated the protective effects and potential mechanisms of wogonin in rat nucleus pulposus cells that had been treated with interleukin-1beta (IL-1β) to induce severe IVDD. An in vivo rat caudal vertebrae needle-stab model was also designed and its validity was evaluated as an IVDD model. The results demonstrated that wogonin suppressed IL-1β-induced inflammatory mediators (iNOS, IL-6 and COX2) and matrix-degrading proteinases (MMP1, MMP3, MMP13 and ADAMTS4). Wogonin also upregulated some of the key components of the extracellular matrix, such as collagen II. Furthermore, we discovered that wogonin exerted anti-inflammatory effects by activating the Nrf2/HO-1-SOD2-NQO1-GCLC signaling axis. Moreover, the IL-1β-induced stimulation of the MAPK signaling pathway was reversed by wogonin treatment. The in vivo MRI and histological results also revealed that wogonin protected the nucleus pulposus from the progression of IVDD. Therefore, wogonin may be a potential agent for the treatment of IVDD.

Keywords: Anti-inflammatory effect; Intervertebral disc degeneration; MAPK; Nrf2/ARE; Wogonin.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Carboxylic Ester Hydrolases / metabolism
  • Collagen Type II / metabolism
  • Collagenases / metabolism
  • Disease Models, Animal
  • Flavanones / therapeutic use*
  • Humans
  • Inflammation Mediators / metabolism
  • Interleukin-1beta / metabolism
  • Intervertebral Disc Degeneration / drug therapy*
  • NF-E2-Related Factor 2 / metabolism
  • Nucleus Pulposus / pathology*
  • Rats
  • Signal Transduction

Substances

  • Anti-Inflammatory Agents
  • Collagen Type II
  • Flavanones
  • Inflammation Mediators
  • Interleukin-1beta
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, rat
  • Carboxylic Ester Hydrolases
  • arylesterase
  • Collagenases
  • wogonin